| Name | Title | Contact Details |
|---|---|---|
Alethia Young |
Chief Financial Officer | Profile |
Julia Tran |
Chief People Officer | Profile |
Sandra Manrriquez |
Associate Director, People Operations and Total Rewards | Profile |
Daisy Leung |
Vice President, Product Strategy and Development | Profile |
Promosome is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Microbion is a clinical stage biopharmaceutical company. Microbion is developing MBN-101 as the first product in the bismuth-thiol class for the treatment of resistant and difficult to treat infections. MBN-101 has broad spectrum, anti-bacterial efficacy against a broad range of pathogens, including multiple priority pathogens or “superbugs”. In addition to anti-bacterial efficacy, MBN-101 also has highly advantageous and product-differentiating capability to prevent and eradicate microbial biofilms. The dual action from this first in class product provides a novel clinical approach to treating infections. Their effectiveness against MRSA, MDR TB, CRE, VRE, and other antibiotic resistant pathogens highlights their potential to provide solutions to the dramatic and alarming increase in global antibiotic resistance.
Guava Technologies, Inc. is a Hayward, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
MediGene, Inc is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
We focus on in-licensing innovative drug candidates that are undergoing or have already completed initial clinical testing for the treatment of various forms of cancer and then seek to further develop these drug candidates for commercial use.